RE:RE:RE:RE:RE:RE:Could it be TFC-1067...?Unlike the first Rodan agreement where customers have to try a diluted version of the formula and sales started from zero, the Allergan agreement would produce immediate existing volumes on day 1.
That means revenue should go to at least pre launch levels the very next day, then royalties to Sirona. Since it appears they are testing this from all angles, they are very likely ensuring a seamless and improved experience for customers - that obviously de-risks the adoption and success factor.
The evidence so far is pointing in the right direction here. I wouldn't be surprised if we peaked out of this trading range in the not so distant future as investors speculate on how the market responds to these additional scientific reports.